Company Overview and News

1
Dalradian Announces Results of its 2018 Meeting of Shareholders

2018-06-22 globenewswire
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") is pleased to announce the results of its 2018 annual meeting of shareholders (the “Meeting”) held today in Toronto, Ontario.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Dalradian files NI 43-101 technical report for the updated mineral resource statement for the Curraghinalt gold deposit

2018-06-22 globenewswire
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") reports that it has filed on SEDAR the National Instrument 43-101 technical report for its updated mineral resource statement for the Curraghinalt gold deposit in Northern Ireland. Highlights of the report were previously announced on May 10, 2018. Because this latest technical report supersedes any previous reports and renders them obsolete, the Company has removed the previous technical report (the 2016 Feasibility Study) from its website and marketing materials.
DRLDF DNA.WT.A DRRLF DALR DNA

33
Top Dalradian shareholder supports Orion Mine takeover offer

2018-06-21 reuters
TORONTO (Reuters) - M&G Investment Management, the biggest shareholder in Dalradian Resources Inc (DNA.TO), said on Thursday it was supportive of a friendly cash takeover offer for Dalradian from private equity group Orion Mine Finance.
DRLDF BLK DNA.WT.A DRRLF DALR DNA

33
Recommended Cash Offer by Orion Mine Finance to Acquire Dalradian Resources Inc.

2018-06-21 globenewswire
TORONTO, June 21, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) and Orion Mine Finance are pleased to announce that the Company and certain affiliates of Orion Mine Finance (collectively, “Orion”) have entered into a definitive arrangement agreement (the “Arrangement Agreement”), whereby Orion will acquire all of the issued and outstanding common shares of the Company (“Dalradian Shares”) by way of a statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).
DRLDF BLK DNA.WT.A FPC OKSWF DRRLF OR OSKGF FPRGF BGMZF DALR DNA

1
Walkabout Resources share spike attracts ASX speeding ticket

2018-05-11 proactiveinvestors.com.au
Walkabout Resources Ltd’s (ASX:WKT) shares have been on a tear, rising from a close of 8.3 cents on Thursday to an intraday high of 10.5 cents today, prompting the ASX to issue a speeding ticket.
DRLDF DNA.WT.A DRRLF WKT DALR DNA

1
Dalradian announces a 46% increase in Measured & Indicated gold ounces and a 32% increase in Inferred gold ounces in new Mineral Resource Statement

2018-05-10 globenewswire
TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") announces an updated mineral resource statement on the Curraghinalt gold deposit in Northern Ireland (“Mineral Resource Statement”), including a 46% increase in gold ounces contained in the Measured and Indicated (“M&I”) categories and a 32% increase in Inferred gold ounces compared to the 2016 resource.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Dalradian intersects 1.54 metres at 61.49 g/t gold from drilling at Curraghinalt

2018-05-01 globenewswire
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) is pleased to report results from 13 step-out drill holes and 30 infill drill holes at the Curraghinalt gold deposit in Northern Ireland.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Walkabout Resources to fly survey over Northern Ireland cobalt-copper-silver targets

2018-04-11 proactiveinvestors.com.au
Walkabout Resources Ltd (ASX:WKT) will fly an airborne electromagnetic (EM) survey over target areas of the Slieve Gallion cobalt-copper-silver joint venture licence area in Northern Ireland.
DRLDF DNA.WT.A DRRLF WKT DALR DNA

1
Walkabout Resources set to unlock lithium, cobalt, gold and graphite opportunities

2018-03-27 proactiveinvestors.com.au
Walkabout Resources Ltd (ASX:WKT) is continuing to focus on lithium exploration in Namibia along with an active cobalt exploration program in Northern Ireland.
DRLDF DNA.WT.A LMI DRRLF WKT DALR DNA

1
Dalradian reports 2017 results with year-end cash of $138 million

2018-03-19 globenewswire
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) announces results for the three months and year ended December 31, 2017, including closing cash and cash equivalents of $138 million1.
DRLDF DNA.WT.A DRRLF DALR DNA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSX:DNA / Dalradian Resources Inc. on message board site Silicon Investor.

MDNA (MC C$36 M) Cash (C$20 M) Approval on P2 Data DNAG - DNAPrint Genomics
Complete Genomics GNOM DNA analysis for human genome Genentech (NYSE:DNA) formerly known as (NYSE:GNE)
Commonwealth Biotechnologies CBTE - Genomics/DNA Seq MTDX - Motion DNA Corporation
LDNA-LARK TECHNOLOGIES DNAP unlocking DNA coding
LDNA: Lark Technologies, Inc. SEDONA Corporation (SDNA)